Are pregnant women allowed to work with biological substances in the laboratory?

Dr. Alexander Heinick

Employers have a special duty to protect pregnant women. Where can employers and pregnant women find relevant information?

If you look in the BioStoffV itself, Pregnant and breastfeeding women not mentioned there. In TRBA 100 "Protective Measures for Activities with Biological Agents in Laboratories," under 6.1 "General Occupational Health Advice," "Pregnancy and Breastfeeding" is only listed as a subsection under "Medical Factors That Can Increase Risk."

In relation to Biomaterials and pregnancy will only be noticed in Maternity Protection Act (MuschG) under Section 11 MuSchG "Unacceptable activities and working conditions for pregnant women". Paragraph 2 states that the employer may not allow a pregnant woman no activities exercise and they no working conditions which they are exposed to a level comparable to Biomaterials the risk group (RG) 2, 3 or 4 (according to BioStoffV) comes or can come into contact, so that this is an irresponsible Danger An irresponsible risk exists in particular if the pregnant woman carries out activities or is exposed to working conditions in which she

  1. with biological substances of RG 4 (according to BioStoffV) or
  2. with the Rubella virus or with Toxoplasma comes or can come into contact (Section 11 Paragraph 2 Sentences 1 and 2 of the MuschG).

This also applies if the Contact with biological substances requires or may require therapeutic measures that are themselves a irresponsible endangerment However, this is considered to be excluded if the pregnant woman has a sufficient Immune protection has.

The above-mentioned statements under Section 11 Paragraph 2 apply to breastfeeding women equally (Section 12 MuschG Paragraph 2).

Every employer is obliged to design the workplace and working conditions of a pregnant or breastfeeding woman in such a way that the life and health of the woman and child are not endangered by the professional activity.

Back to blog

More articles in the AGCT Genetic Engineering report